Biological
VRC-01 clinical trials
Also written VRC01.
- studies test it
- 11
- open now
- 1
- in phase 3
- 0
- first study started
- 2014
Keep track of what changes. Save the VRC-01 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- VRC01
- 11
Studies by the year they started
11 studies that test it; most in 2015 (4)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 11
National Institute of Allergy and Infectious Diseases (NIAID) (11)
Often tested with
Tested in the same studies.
VRC-01LS (2) · VRC07-523LS (2) · Nevirapine (1) · Lopinavir-ritonavir drug combination (1) · Raltegravir (1) · Dolutegravir (1)
Studies
Open first, then newest update. How each study uses VRC-01 is read from its arms, and is right about nine times in ten.
Testing it · 11
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV RemissionRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT02140255Written as VRC01
- Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV InfectionCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02591420Written as VRC01
- Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02797171Written as VRC01
- Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in Infants With HIV Receiving Combination Antiretroviral TherapyCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT03208231Written as VRC01
- Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed InfantsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02256631Written as VRC01
- Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With MenCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT02716675Written as VRC01
- Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in WomenCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT02568215Written as VRC01
- Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02411539Written as VRC01
- Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV InfectionCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT02664415Written as VRC01
- Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment InterruptionCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02463227Written as VRC01
- Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02165267Written as VRC01